{"nctId":"NCT00833703","briefTitle":"Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation","startDateStruct":{"date":"2009-01"},"conditions":["Heart Defects, Congenital"],"count":49,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"Clopidogrel 0.2 mg/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Clopidogrel"]}],"interventions":[{"name":"Clopidogrel","otherNames":["SR25990","Plavix"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients randomized in the CLARINET study,\n* Still receiving the study drug,\n* Palliative systemic-to-pulmonary artery shunt still in place at 1 year of age,\n* Investigator's decision to continue based on his/her judgment of the expected benefit / risk of continuing treatment with study drug,\n* Signed informed consent to participate in the long-term safety study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Bleeding Events","description":"All bleeding events experienced during the study period were collected as for any Adverse Event.\n\nThe 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths","description":"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.\n\nParticipants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants According to Bleeding Type/Etiology","description":"For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":23},"commonTop":["Any infections and infestations","Any gastrointestinal disorders","Any general disorders and administration site conditions","Upper respiratory tract infection","Any respiratory, thoracic and mediastinal disorders"]}}}